Cargando…

Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report

BACKGROUND: Plasma cell leukemia (PCL) is a rare lymphoproliferative disorder considered to be a variant of multiple myeloma. It is an aggressive disease with a poor clinical response to standard chemotherapeutic agents. CASE PRESENTATION: A novel regimen consisting of bortezomib, doxorubicin, and d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, Steven M, George, Tracy, Cherry, Athena M, Medeiros, Bruno C
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2644294/ https://www.ncbi.nlm.nih.gov/pubmed/19192311 http://dx.doi.org/10.1186/1757-1626-2-121

Ejemplares similares

Bortezomib, Lenalidomide and Dexamethasone Combination Induced Complete Remission in Relapsed/Refractory Plasmablastic Lymphoma: Case Report of a Potential Novel Treatment Approach
por: Sabry, Waleed, et al.
Publicado: (2022)

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
por: Andersen, Kristian T., et al.
Publicado: (2020)

Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen
por: Jacobus, S J, et al.
Publicado: (2016)

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
por: Zhou, Xiang, et al.
Publicado: (2020)

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
por: Richard, Shambavi, et al.
Publicado: (2021)

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
por: Spencer, Andrew, et al.
Publicado: (2018)

Bortezomib-Based Regimens and Plasma Cell Leukemia
por: Bolaman, Ali Zahit
Publicado: (2021)

A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma
por: Becker, P S, et al.
Publicado: (2016)

Optimizing survival outcomes with post‐remission therapy in acute myeloid leukemia
por: Medeiros, Bruno C., et al.
Publicado: (2019)

Immunoglobulin D Multiple Myeloma, Plasma Cell Leukemia and Chronic Myelogenous Leukemia in a Single Patient Treated Simultaneously with Lenalidomide, Bortezomib, Dexamethasone and Imatinib
por: Ali, Naveed, et al.
Publicado: (2016)

First Case of Nodular Localized Primary Cutaneous Amyloidosis Treated With Bortezomib and Dexamethasone
por: Khan, Noman Ahmed Jang, et al.
Publicado: (2021)

DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma
por: Kropff, Martin, et al.
Publicado: (2009)

Treatment of Coexisting Chronic Neutrophilic Leukemia and Light Chain Multiple Myeloma with Hydroxyurea, Bortezomib, and Dexamethasone
por: Taiwo, Evelyn, et al.
Publicado: (2014)

Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
por: Sauer, Sandra, et al.
Publicado: (2023)

Successful treatment with bortezomib-containing regimen of primary plasma cell leukemia: a case report
por: Obeidat, Mohammad Bader, et al.
Publicado: (2020)

A Case of Renal Synovial Sarcoma: Complete Remission was Induced by Chemotherapy with Doxorubicin and Ifosfamide.
por: Park, Soo-Jin, et al.
Publicado: (2004)

Complete remission of lambda light chain myeloma presenting with acute renal failure following treatment with bortezomib and steroids
por: Pavan, M., et al.
Publicado: (2010)

Bortezomib/dexamethasone: Covid-19 pneumonia: case report
Publicado: (2021)

Bortezomib/dexamethasone: COVID-19 infection: case report
Publicado: (2021)

Daratumumab–bortezomib–dexamethasone use in relapsed POEMS syndrome
por: Khwaja, Jahanzaib, et al.
Publicado: (2022)

Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis
por: Brennan, Xavier, et al.
Publicado: (2022)

A Case of Multiple Myeloma with Metachronous Chronic Myeloid Leukemia Treated Successfully with Bortezomib, Dexamethasone, and Dasatinib
por: Alsidawi, Samer, et al.
Publicado: (2014)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
por: Rosiñol, Laura, et al.
Publicado: (2023)

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
por: Hjorth, Martin, et al.
Publicado: (2012)

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2018)

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
por: O’Connor-Byrne, N., et al.
Publicado: (2019)

Bortezomib-induced diffuse alveolar hemorrhage in a patient with plasma cell leukemia
por: Wirth, Ingrid M., et al.
Publicado: (2020)

Therapeutic effect of bortezomib for primary plasma cell leukemia followed by auto/allo stem cell transplantation
por: Ozasa, Ryotaro, et al.
Publicado: (2012)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
por: Hassan Zafar, Mir Sadaqat, et al.
Publicado: (2018)

P895: DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) ALONE IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF LEPUS
por: Fu, W., et al.
Publicado: (2022)

Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib
por: Pandey, Manu R., et al.
Publicado: (2017)

Alternating bortezomib-dexamethasone and lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma aged over 75 years
por: Yokoyama, Akihiro, et al.
Publicado: (2022)

Comparison of bortezomibcyclophosphamide- dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients
por: Ciftciler, Rafiye, et al.
Publicado: (2020)

P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL
por: Sonneveld, P, et al.
Publicado: (2022)

The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
por: Hashimoto, Shigeo, et al.
Publicado: (2016)

Bortezomib/dexamethasone/oxytetracycline: Chalazia, blepharitis and lack of efficacy: case report
Publicado: (2021)

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation
por: Fouquet, Guillemette, et al.
Publicado: (2014)

Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone
por: Erath, Alexandra, et al.
Publicado: (2020)

Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients
por: Qian, Wensi, et al.
Publicado: (2020)

P21 EFFECTIVENESS AND SAFETY OF DELAYED BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE (VTD) REGIMEN
por: Del Fabro, V., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a8s52nhb6dvseo9k9t6b56dq3c